Intratumoral delivery and therapeutic efficacy of nanoparticle-encapsulated anti-tumor siRNA following intrapulmonary administration for potential treatment of lung cancer

References

• Agrawal N, Dasaradhi PV, Mohmmed A, Malhotra P, Bhatnagar RK, Mukherjee SK. 2003. RNA interference: biology, mechanism, and applications. Microbiol Mol Biol Rev. 67:657–685.
   PubMed Web of Science ®Google Scholar
• Armstead, A, Li, B. 2016. In vitro inflammatory effects of hard metal (WC–Co) nanoparticle exposure. IJN. 11:6195–6206.
   Google Scholar
• Ashley AC, Deschamps C, Alberts SR. 2006. Impact of prognostic factors on clinical outcome after resection of colorectal pulmonary metastases. Clin Colorectal Cancer. 6:32–37.
   PubMed Web of Science ®Google Scholar
• Aydar E, Palmer CP, Djamgoz MB. 2004. Sigma receptors and cancer: possible involvement of ion channels. Cancer Res. 64:5029–5035.
   PubMed Web of Science ®Google Scholar
• Banerjee R, Tyagi P, Li S, Huang L. 2004. Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int J Cancer. 112:693–700.
   PubMed Web of Science ®Google Scholar
• Chono S, Li SD, Conwell CC, Huang L. 2008. An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. J Control Release. 131:64–69.
   PubMed Web of Science ®Google Scholar
• Chono S, Tanino T, Seki T, Morimoto K. 2006. Influence of particle size on drug delivery to rat alveolar macrophages following pulmonary administration of ciprofloxacin incorporated into liposomes. J Drug Target. 14:557–566.
   PubMed Web of Science ®Google Scholar
• de Nigris F, Balestrieri ML, Napoli C. 2006. Targeting c-Myc, Ras and IGF cascade to treat cancer and vascular disorders. Cell Cycle. 5:1621–1628.
   PubMed Web of Science ®Google Scholar
• Dekhuijzen PN, Vincken W, Virchow JC, Roche N, Agusti A, Lavorini F, van Aalderen WM, Price D. 2013. Prescription of inhalers in asthma and COPD: towards a rational, rapid and effective approach. Respir Med. 107:1817–1821.
   PubMed Web of Science ®Google Scholar
• Durcan N, Murphy C, Cryan SA. 2008. Inhalable siRNA: potential as a therapeutic agent in the lungs. Mol Pharm. 5:559–566.
   PubMed Web of Science ®Google Scholar
• Gao G, Jiang J, Liang X, Zhou X, Huang R, Chu Z, Zhan Q. 2009. A meta-analysis of platinum plus gemcitabine or vinorelbine in the treatment of advanced non-small-cell lung cancer. Lung Cancer. 65:339–344.
   PubMed Web of Science ®Google Scholar
• Gomes-da-Silva LC, Simoes S, Moreira JN. 2014. Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology. Cell Mol Life Sci. 71:1417–1438.
   PubMed Web of Science ®Google Scholar
• Grothey A. 2006. Future directions in vascular endothelial growth factor-targeted therapy for metastatic colorectal cancer. Semin Oncol. 33:S41–S49.
   PubMed Web of Science ®Google Scholar
• Haghiralsadat F, Amoabediny G, Naderinezhad S, Nazmi K, De Boer JP, Zandieh-Doulabi B, Forouzanfar T, Helder MN. 2017. EphA2 targeted doxorubicin-nanoliposomes for osteosarcoma treatment. Pharm Res. 34:2891–2900.
   PubMed Web of Science ®Google Scholar
• Halaby MJ, Yang DQ. 2007. p53 translational control: a new facet of p53 regulation and its implication for tumorigenesis and cancer therapeutics. Gene. 395:1–7.
   PubMed Web of Science ®Google Scholar
• Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ. 2005. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 65:8984–8992.
   PubMed Web of Science ®Google Scholar
• Jaggi AS, Singh N. 2012. Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. Toxicology. 291:1–9.
   PubMed Web of Science ®Google Scholar
• Kanehira Y, Togami K, Tada H, Chono S. 2016. Tumor distribution and anti-tumor effect of doxorubicin following intrapulmonary administration to mice with metastatic lung tumor. J Drug Deliv Sci Technol. 33:143–148.
   Web of Science ®Google Scholar
• Kaneko K, Togami K, Yamamoto E, Wang S, Morimoto K, Itagaki S, Chono S. 2016. Sustained distribution of aerosolized PEGylated liposomes in epithelial lining fluids on alveolar surfaces. Drug Deliv Transl Res. 6:565–571.
   PubMed Web of Science ®Google Scholar
• Kim HS, Kim JH, Kim B, Choi HC, Kwon JH, Choi DR. 2013. Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 71:1591–1597.
   PubMed Web of Science ®Google Scholar
• Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M, European Society of Clinical Pharmacy Special Interest Group on Cancer Care. 2008. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol. 61:903–909.
   PubMed Web of Science ®Google Scholar
• Lee HC, Chen FF, Lo CC, Wang CJ, Lo WC, Luh SP. 2010. Metastasis of gastric carcinoma to the thyroid and lung: a case report and review of literature. J Zhejiang Univ Sci B. 11:542–546.
   PubMed Web of Science ®Google Scholar
• Lehnert BE. 1992. Pulmonary and thoracic macrophage subpopulations and clearance of particles from the lung. Environ Health Perspect. 97:17–46.
   PubMed Web of Science ®Google Scholar
• Li P, Shi JX, Dai LP, Chai YR, Zhang HF, Kankonde M, Kankonde P, Yu BF, Zhang JY. 2016. Serum anti-MDM2 and anti-c-Myc autoantibodies as biomarkers in the early detection of lung cancer. Oncoimmunology. 5:e1138200.
   PubMed Web of Science ®Google Scholar
• Li SD, Chono S, Huang L. 2008. Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol Ther. 16:942–946.
   PubMed Web of Science ®Google Scholar
• Li SD, Huang L. 2006. Surface-modified LPD nanoparticles for tumor targeting. Ann N Y Acad Sci. 1082:1–8.
   PubMed Web of Science ®Google Scholar
• McCaffrey AP, Meuse L, Pham TT, Conklin DS, Hannon GJ, Kay MA. 2002. RNA interference in adult mice. Nature. 418:38–39.
   PubMed Web of Science ®Google Scholar
• Moschos SA, Frick M, Taylor B, Turnpenny P, Graves H, Spink KG, Brady K, Lamb D, Collins D, Rockel TD, et al. 2011. Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense. Mol Ther. 19:2163–2168.
   PubMed Web of Science ®Google Scholar
• Murakami T, Cardones AR, Hwang ST. 2004. Chemokine receptors and melanoma metastasis. J Dermatol Sci. 36:71–78.
   PubMed Web of Science ®Google Scholar
• Musolino, C, Allegra, A, Innao, V, Allegra, A G, Pioggia, G, Gangemi, S. 2017. Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma. Mediators Inflamm. 2017:1–24.
   Google Scholar
• Oh YK, Park TG. 2009. siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev. 61:850–862.
   PubMed Web of Science ®Google Scholar
• Rossi A, Martelli O, Di Maio M. 2013. Treatment of patients with small-cell lung cancer: from meta-analyses to clinical practice. Cancer Treat Rev. 39:498–506.
   PubMed Web of Science ®Google Scholar
• Saitoh Y, Terada N, Saitoh S, Ohno N, Jin T, Ohno S. 2012. Histochemical analyses and quantum dot imaging of microvascular blood flow with pulmonary edema in living mouse lungs by "in vivo cryotechnique". Histochem Cell Biol. 137:137–151.
   PubMed Web of Science ®Google Scholar
• Schabath MB, Nguyen A, Wilson P, Sommerer KR, Thompson ZJ, Chiappori AA. 2014. Temporal trends from 1986 to 2008 in overall survival of small cell lung cancer patients. Lung Cancer. 86:14–21.
   PubMed Web of Science ®Google Scholar
• Song E, Zhu P, Lee SK, Chowdhury D, Kussman S, Dykxhoorn DM, Feng Y, Palliser D, Weiner DB, Shankar P, et al. 2005. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol. 23:709–717.
   PubMed Web of Science ®Google Scholar
• Teng JP, Yang ZY, Zhu YM, Ni D, Zhu ZJ, Li XQ. 2017. The roles of ARHGAP10 in the proliferation, migration and invasion of lung cancer cells. Oncol Lett. 14:4613–4618.
   PubMed Web of Science ®Google Scholar
• Togami K, Chono S, Morimoto K. 2012. Aerosol-based efficient delivery of clarithromycin, a macrolide antimicrobial agent, to lung epithelial lining fluid and alveolar macrophages for treatment of respiratory infections. J Aerosol Med Pulm Drug Deliv. 25:110–115.
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. 2015. Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108.
   PubMed Web of Science ®Google Scholar
• Woods A, Patel A, Spina D, Riffo-Vasquez Y, Babin-Morgan A, de Rosales RT, Sunassee K, Clark S, Collins H, Bruce K, et al. 2015. In vivo biocompatibility, clearance, and biodistribution of albumin vehicles for pulmonary drug delivery. J Control Release. 210:1–9.
   PubMed Web of Science ®Google Scholar
• Yang Y, Hu Y, Wang Y, Li J, Liu F, Huang L. 2012. Nanoparticle delivery of pooled siRNA for effective treatment of non-small cell lung cancer. Mol Pharm. 9:2280–2289.
   PubMed Web of Science ®Google Scholar
• Zarogoulidis P, Chatzaki E, Porpodis K, Domvri K, Hohenforst-Schmidt W, Goldberg EP, Karamanos N, Zarogoulidis K. 2012. Inhaled chemotherapy in lung cancer: future concept of nanomedicine. Int J Nanomedicine. 7:1551–1572.
   PubMed Web of Science ®Google Scholar